| 货号 | MAB797 |
| 别名 | BP2; IBP2; IBP-2; IGF-binding protein 2; IGFBP-2; IGF-BP53; insulin-like growth factor binding protein 2 (36kD); insulin-like growth factor binding protein 2, 36kDa; insulin-like growth factor-binding protein 2 | 全称 | Insulin-like Growth Factor Binding Protein 2 |
| 反应种属 | Mouse |
| 应用 | Western Blot,Neutralization |
| 目标/特异性 | Detects mouse IGFBP-2 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human IGFBP-1, -2, -3, -4, -5, -6, recombinant mouse IGFBP-1, -3, -5, or -6 is observed. |
| 使用方法 | Western Blot: 1 µg/mL Neutralization: Measured by its ability to neutralize IGFBP‑2 inhibition of IGF‑II-dependent proliferation in the MCF‑7 human breast cancer cell line. Karey, K. P. et al. (1988) Cancer Research 48:4083. The Neutralization Dose (ND50) is typically 5‑20 µg/mL in the presence of 0.75 µg/mL Recombinant Mouse IGFBP‑2 and 30 ng/mL Recombinant Mouse IGF‑II. |
| 来源 | Monoclonal Rat IgG2A Clone # 150101 |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 3485 (Human); 16008 (Mouse) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Patched1 inhibits epidermal progenitor cell expansion and basal cell carcinoma formation by limiting Igfbp2 activity. | |
| 纯化方式 | Protein A or G purified from hybridoma culture supernatant |
| 免疫原 | Mouse myeloma cell line NS0-derived recombinant mouse IGFBP‑2 Glu35-Gln305 Accession # CAA57270 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Mouse |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.5 mg/mL in sterile PBS. |
| 背景 | The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and at least four additional low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBPs, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF. Mouse IGFBP-2 cDNA encodes a 305 amino acid (aa) precursor protein with a 34 aa residue signal peptide and a 271 aa mature protein. Mouse and human IGFBP-2 share approximately 82% aa identity. IGFBP-2 contains an integrin receptor recognition sequence (RGD sequence) but lacks potential N-linked glycosylation sites. During development, IGFBP-2 is expressed in a number of tissues. The highest expression level is found in the central nervous system. In adults, high expression levels are also detected in the central nervous system and in a number of reproductive tissues. IGFBP-2 binds preferentially to IGF-II, exhibiting a 2-10 fold higher affinity for IGF-II than for IGF-I. |
| 运输条件 | Blue Ice |
| 存放说明 | -20℃ |
| 参考文献 |
|
IGFBP‑2 Inhibition of IGF‑II-dependent Cell Proliferation and Neutralization by Mouse IGFBP‑2 Antibody. Recombinant Mouse IGFBP‑2 (Catalog # 797-B2) inhibits Recombinant Mouse IGF‑II (Catalog # 791-MG) induced proliferation in the MCF‑7 human breast cancer cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Mouse IGF‑II (30 ng/mL) activity elicited by Recombinant Mouse IGFBP‑2 (0.75 µg/mL) is neutralized (green line) by increasing concentrations of Rat Anti-Mouse IGFBP‑2 Monoclonal Antibody (Catalog # MAB797). The ND50 is typically 5-20 µg/mL. |
